MDR - PMCF Study for Taperloc Complete Stems
← catalyst calendarNCT04028687 · readout in 2,003 d
Sponsored by Zimmer Biomet (industry) · ZBH — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
820estimated
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-02-13 | actual | When the study began enrolling |
| Primary completion | 2032-02-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-02-12 | estimated | The whole study's end, after follow-up |
| First posted | 2019-07-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-03-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hip Arthritis
- Hip Disease
- Hip Fractures
- Hip Injuries
- Hip Pain Chronic
Intervention
- Device: Taperloc Complete Stem
Primary outcome
what the primary-completion date above is the date OFDevice Safety assessed through the frequency and incidence of revisions, complications and Adverse Events.
measured Out to 10 Years
Permalink · ZBH's whole pipeline · Catalyst calendar · Every registered study · What changed